由于FDA无根据的批准传闻，白子蛋白需求激增，尽管缺乏自闭症益处，但导致短缺和风险。 A surge in demand for leucovorin, fueled by unfounded FDA approval rumors, caused shortages and risks despite lack of proven autism benefits.

2025年底，联邦官员暗示FDA很快将批准白叶酸用于自闭症治疗后，自闭症儿童家长对其兴趣激增，导致广泛非适应症使用、全国短缺以及来自加拿大和西班牙的临时进口。 Interest in leucovorin, a chemotherapy drug, surged among parents of autistic children after federal officials in late 2025 suggested the FDA would soon approve it for autism, leading to widespread off-label use, a national shortage, and temporary imports from Canada and Spain. 包括Paul Offit博士在内的专家提醒注意,药物的流行程度超过科学证据,指出这只能帮助一小部分脑叶酸缺乏症(一种不同于自闭症的稀有情况),而这种缺陷是基于有限的早期研究。 Experts, including Dr. Paul Offit, caution that the drug’s popularity exceeds scientific evidence, noting it may only help a small subset with cerebral folate deficiency—a rare condition distinct from autism—based on limited early studies. 主要医疗团体不赞成使用这种药物,对未经证实的治疗和潜在风险发出警告。 Major medical groups have not endorsed its use, warning against unproven treatments and potential risks.